COLLOIDAL OATMEAL CHEAT SHEET
Oatmeal has been used as a skin care ingredient since 2000 BC in ancient Egypt, where whole oats were used in soothing baths. Colloidal oat has been the subject of dedicated skin care research starting in the 1950s. After > 30 clinical studies comprised of over 3000 patients including conditions associated with a compromised skin barrier, colloidal oat is now recognized as a skin protectant by …
Oatmeal has been used as a skin care ingredient since 2000 BC in ancient Egypt, where whole oats were used in soothing baths. Colloidal oat has been the subject of dedicated skin care research starting in the 1950s. After > 30 clinical studies comprised of over 3000 patients including conditions associated with a compromised skin barrier, colloidal oat is now recognized as a skin protectant by … 
During the recent DERM2O22 NP/PA CME conference held July 28-31, 2022, Drs. David Cohen, Brad Glick, and Adam Friedman led a case-based panel discussion on atopic dermatitis (AD) treatment initiation and monitoring. This article provides a summary of their discussion and recommendations.
CASE 1
51-year-old male with a 20-year history of AD. The patient was first seen in September 2015 with BSA … 
Colloidal oatmeal has a long history of use in the treatment of dermatologic disease. Oat is composed of various phytochemicals which contribute to its wide-ranging function and clinical use in atopic dermatitis and other skin conditions resulting from an impaired skin barrier and inflammation.
OAT COMPOSITION & BENEFITS
The main components of colloidal oatmeal are polysaccharides (including … 
Atopic dermatitis is a common, chronic, life-altering disease. With its visibility and debilitating pruritus, atopic dermatitis significantly impacts our patients’ quality of life. For those with resistant and extensive disease, we are happy to have numerous new systemic agents at our disposal, one being tralokinumab, an IL-13 antagonist. We continue our series, Therapeutic Cheat Sheet, with a c … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Neal Bhatia (a board-certified Dermatologist who serves as Director of Clinical Dermatology at Therapeutics Clinical Research ) about the latest with JAK inhibitors. Watch as he summarizes the most recent trials, approvals, and developments. Plus why doctors shouldn't be afraid to dive in w … 